New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 8, 2014
10:25 EDTDRRX, DRRX, PCRX, PCRXSummer Street's chief scientific officer holds analyst/industry conference call
Chief Scientific Officer Classen discusses Durect's (DRRX) Posidur for post-operative pain, its safety and whether it could be disruptive to Pacira Pharmaceuticals (PCRX) on an Analyst/Industry conference call to be held on January 8 at 11 am.
News For DRRX;PCRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 11, 2014
16:09 EDTDRRXDURECT provides update on FDA communication over POSIDUR
DURECT announced that it has received meeting minutes from its face-to-face meeting with the FDA on September 23, regarding the POSIDUR program. In the February Complete Response Letter, the FDA indicated that multiple safety trials would be required to support a broad indication. DURECT inquired whether it would be possible to expedite approval by pursuing an initial indication of soft tissue post-surgical analgesia without conducting additional trials. The company said the FDA has indicated that in this scenario, it should be acceptable to conduct only one additional soft tissue clinical trial, the size of which is not yet defined, to generate the data required for product approval, including safety data for POSIDUR compared to a non-SABER containing comparator and also product efficacy. "Based on the Complete Response Letter we anticipated that we would be required to do additional safety trials," stated James Brown, President and CEO of DURECT. "Over the coming months, we expect to have further communications with the FDA to refine the path forward."

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use